Stem Cell Therapeutics Corp. Invited to Present at Florida's Largest Bioscience Forum
October 20 2008 - 11:43AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) announces
today Dr. Alan Moore, President and CEO, will be participating in a
panel discussion at BioFlorida's 11th Annual Conference to be held
October 19-21 at the Ritz-Carlton in Amelia Island, Florida. The
panel discussion, titled "Individualized Medicine", will be chaired
by Dr. Todd E. Golde, Professor and Consultant in the Department of
Neuroscience at the Mayo Clinic Jacksonville. In addition to Dr.
Moore, the panel includes Dr. Daniel Kelly, Scientific Director and
Professor at the Burnham Institute for Medical Research and Dr.
Dennis Steindler, Professor of Neuroscience and Neurosurgery at the
University of Florida, College of Medicine.
The panel discussion will highlight how discovery science is
leading to individualized and personal medicine, specifically in
relation to stem cell based therapies, and what the potential for
translation into the commercial sector. Dr. Alan Moore will address
progress in clinical trials for stem cell based therapies.
About BioFlorida's 11th Annual Conference: The 2008 BioFlorida
Annual Conference on October 19-21 at The Ritz-Carlton in Amelia
Island brings together leading national speakers as the state's
largest bioscience forum reaches key business and scientific
leaders from all sectors of the industry. In its 11th year, this
premier conference showcases Florida's bioscience technologies with
sessions tailored to those involved in the business of medical
device, biotechnology and pharmaceutical research. This year's
pivotal conference focuses on product development stages with
topics that include partnering, clinical trials and drug
discovery.
The forum provides attendees with insight into how the industry
is dealing with today's economic and political environment.
Attendees gain knowledge from distinguished speakers that include
Yank D. Coble Jr., MD from University of North Florida; James C.
Greenwood from the Biotechnology Industry Organization; Bob Ingram
from GlaxoSmithKline; Stephen N. Oesterle, MD from Medtronic; and
Jacksonville Mayor John Peyton. "Florida is ranked as one of the
top five regions worldwide for attracting biotechnology companies
by Fierce Biotech," said Russell Allen, president of BioFlorida,
"The outcomes and dialogue generated during this annual conference
guide critical efforts to further improve the business climate for
bioscience companies throughout Florida."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024